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Abstract
The relationship between inflammation and insulin
resistance is complex and not fully understood.
Patients with rheumatoid arthritis are at increased risk
of mortality from cardiovascular disease, which is
known to be associated with insulin resistance. In the
previous issue of Arthritis Research & Therapy, Ormseth
and colleagues report the results of an 8-week trial of
pioglitazone, an agent commonly used to treat type 2
diabetes mellitus, upon the DAS-28 (disease activity
score using 28 joint counts). Modest improvements in
the DAS-28 CRP (DAS-28 C-reactive protein) were
shown, with no effect on DAS-28 ESR (DAS-28
erythrocyte sedimentation rate). Other variables that
improved with pioglitazone were the CRP, IL-6, and
patient-reported assessment of global health. The
authors discuss the contribution of insulin resistance
to the inflammation noted in rheumatoid arthritis.
Disease-modifying anti-rheumatic drugs (DMARDs) have
effectively reduced long-term disability and structural dis-
ease associated with rheumatoid arthritis (RA). However,
patients with RA continue to suffer from a variety of
extra-articular manifestations, including cardiovascular
disease (CVD). The reasons for this risk, which is associ-
ated with increased mortality, are not fully understood.
In addition to traditional CVD risk factors, there is evi-
dence to suggest that chronic inflammation induced by
cytokine-mediated inflammatory pathways increases risk,
perhaps by affecting endothelial function or insulin resist-
ance or both. The relationship between insulin resistance
and inflammation is not fully elucidated; inflammation is
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known to be associated with insulin resistance, and hyper-
insulinemia is also associated with inflammation.
In the previous issue of Arthritis Research & Therapy,
Ormseth and colleagues [1] further explore the relation-
ship between inflammation, insulin resistance, and RA by
studying the effects of 8 weeks of pioglitazone, a thiazoli-
dinedione used to treat type 2 diabetes mellitus, in a
double-blinded, placebo-controlled, crossover study of 34
subjects with ‘moderate disease activity’ due to RA. The
study population consisted largely of non-obese females
with a mean baseline C-reactive protein (CRP) of 4.58 and
DAS-28 CRP (disease activity score using 28 joint counts-
CRP) of more than 4.4. Over half of the subjects were
taking corticosteroids at study entry; 70% were taking
methotrexate, and over half were taking ‘biologic’ therapy
(class not specified). Erosive disease was present in the
majority. The study was conducted at a single center and
lasted for 3 years. The primary outcome measure was the
change in the DAS-28; secondary outcome measures were
individual components of the DAS-28, IL-6 (pg/mL),
tumor necrosis factor-alpha (pg/mL), change in the modi-
fied health assessment questionnaire, and the homeostatic
model assessment (HOMA) for insulin resistance, a stand-
ard measurement of insulin resistance. Treatment with
pioglitazone resulted in a 9% improvement in the DAS-28
CRP (P=0.046) but had no effect on the DAS-28 ESR
(DAS-28 erythrocyte sedimentation rate) (0.6%, P=0.92 ).
Other significant results were a nearly 50% reduction in
CRP (mg/dL) (P <0.001), an approximately 70% reduction
in IL-6 (P=0.01), and an 11% improvement in the
patient-reported visual analogue scale for global health. As
expected, the HOMA improved by 26% (95% confidence
interval −43.8% to −3.7%).
Results from this small but provocative study under-
score the complex interplay between inflammation and in-
sulin resistance. The parallel improvements in IL-6 and
insulin resistance are in keeping with the known, strong
association between insulin resistance and IL-6 [2]. The
reductions in IL-6, CRP, and DAS-28 CRP in the study by
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2013, 15:124
http://arthritis-research.com/content/15/6/124Ormseth and colleagues highlight the known inhibitory
effects of pioglitazone on pro-inflammatory cytokines [3].
The improvements in DAS-CRP, and not DAS-ESR, sug-
gest that the independent effects of pioglitazone on IL-6
may have accounted for much of the reduction in disease
activity, further suggested by the lack of improvement
in the tender and swollen joint counts. This link between
IL-6 inhibition and insulin resistance was also observed in
an open-label study of tocilizumab, an inhibitor of IL-6, in
11 non-diabetic subjects with steroid-dependent, stable
RA; the HOMA significantly improved at 12 weeks [4].
Examining the RA treatment effects of agents approved
for other indications like diabetes or hyperlipidemia,
known risk factors for CVD, is not new. In the Trial of
Atorvastatin Rheumatoid Arthritis, a randomized study of
atorvastatin in patients with active RA, investigators dem-
onstrated modest improvements in the DAS-28, along
with reductions in IL-6 and CRP [5]. The authors suggest
considering the use of atorvastatin as an adjunct to
DMARD therapy in an effort to mitigate disease activity
and provide ‘vascular’ protection. Although the use of
atrovastatin and pioglitazone as primary RA treatments is
not justified, use of these agents in patients with RA and
hyperlipidemia or type 2 diabetes mellitus may be worth-
while. Studies such as these, along with studies of bio-
logical agents in RA that affect inflammatory cytokine
pathways, provide insights into why patients with RA are
at increased risk of CVD. It is likely that more complete
immunosuppression will reduce CVD risk but that ad-
junctive therapy with other agents like statins and thiazoli-
dinediones, which possess immunomodulatory effects,
may have a role in future RA therapeutic regimens. In the
future, the ‘complete’ treatment of RA will include elimin-
ation of the direct effects of uncontrolled inflammation on
joints as well as mitigation of CVD and diabetes, which
appear to be related to the ongoing inflammatory process.
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